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Introduction
Breast cancer is the major cancer affecting women with a lifetime risk of over 10% in the general population in Western countries. The prevalence is however, much lower in Asia and many economically developing countries (1) . However, Asian immigrants to the United States acquire the prevalence of that country within one generation, indicating a strong effect of environmental exposures. Although the majority of primary breast cancer is estrogen driven and often responsive to endocrine treatment, many patients progress to estrogen-insensitive disease with poor prognosis (2) (3) . A critical determinant of such progression is the loss of the estrogen receptor-α (ER), which is associated with a more aggressive tumor phenotype and the loss of sensitivity to endocrine therapies such as tamoxifen (3) . ER can stimulate cellular proliferation via progesterone receptor (PgR) induction and transcriptional up-regulation of cyclin D1, leading to enhanced cell cycle progression, whereas ER loss has been associated with enhanced motility and metastatic abilities of breast cancer cells. Although loss of ER activity and expression has critical consequences for breast cancers, it generally occurs without evidence of ER gene mutation or deletion. Alterations in ER levels can be regulated at transcriptional or post-transcriptional stages, or through epigenetic mechanisms (4) . Given that the prevalence of breast cancer varies between different geographic locations, potential modifiable environmental, dietary and lifestyle determinants may also influence the ER status.
The insulin-like growth factor (IGF) family has been identified as an additional driver of breast cancer. The mitogenic and anti-apoptotic signals are mediated via the IGF type I receptor (IGF-IR) and its downstream targets MAPK/ERK or PI3K/Akt. The ER and IGF-IR signaling systems are tightly linked and subject to feedback crosstalk. For example, estrogen and IGFs co-regulate several genes that affect breast cancer outcome (5) . In addition, hyperactive IGF-IR/PI3K/Akt signaling has been implicated to contribute in the acquisition of 5 resistance to endocrine therapy during breast cancer progression (6) . Estrogen increases IGF-IR mRNA and anti-estrogens, like tamoxifen, can reduce serum IGF-I levels and IGFmediated growth (7) (8) . Conversely, blocking IGF actions can inhibit estrogen-mediated growth (9) . Similar to ER activity, various anthropometric, lifestyle and dietary factors can influence the IGF system with impact on cancer development and progression.
In recent years, mechanisms involved in mediating cancer chemopreventive effects of naturally derived plant polyphenols from green tea and coffee have been widely studied in several neoplasias including breast and prostate cancer (10) (11) (12) (13) . However, there have been few translational studies on anticancer effects of coffee in relation to ER status in breast cancer. Prospective and retrospective epidemiological studies show an association between coffee consumption and a significantly reduced risk, delayed onset and reduced growth of breast cancer (14) (15) . Coffee beans are one of the richest dietary sources of the antioxidants caffeine and the plant phenolic compound caffeic acid, both of which may be mechanistically involved in the cancer suppressive properties of coffee. Various dietary and lifestyle factors are also known to influence the sensitivity to cancer treatment (10, 16) . In line with this, our group recently showed in a subset of the present study cohort, that moderate to high coffee consumption was associated with improved disease-free survival among ER + tamoxifentreated women (17) .
The aim of the present translational study was to investigate the effect of coffee consumption on tumor characteristics and disease-free survival in an extended cohort of women with breast cancer in Sweden, and to establish underlying molecular mechanisms by which coffee constituents may impact on breast cancer cell growth in relation to ER status. Understanding how exposure to components of our daily diet can modify tumor growth or molecular
Research. 
Materials and methods

Reagents
All chemicals and reagents were purchased from Sigma Aldrich (St Louis, MO, USA) unless stated otherwise. Cell culture media, penicillin/streptomycin and fetal bovine serum (FBS) were purchased from Invitrogen (Paisley, UK). For immunoblotting, the anti-ERα antibody 
Study Population
The present study is based on an extended cohort of 1090 women, aged 24-99 years, diagnosed with primary invasive breast cancer between October 2002 and December 2012 at the Skåne University Hospital in Lund, Sweden, without preoperative treatment and with no other cancer history within the past 10 years. This is an ongoing cohort (BC Blood study) and is now updated to include almost twice as many women as recently reported by our group (17) . The inclusion and exclusion criteria were compliant to the REporting recommendations for tumor MARKer prognostic study (REMARK) guidelines (18) . During the preoperative visit, body measurements of weight, height, waist and hip circumference, and breast volume were collected (as previously described, (19) (20) 
Cell culture
The human breast cancer cell lines MCF-7, T47D (both ERα-positive) and MDA-MB-231 (ERα-negative) were purchased from and validated by ATCC-LGC Standards (Manassas, VA, USA) and maintained in Dulbecco's Modified Eagle's Medium supplemented with 10% FBS and antibiotics (100U/ml penicillin and 100 μg/ml streptomycin) in a humidified 5% CO 2 atmosphere at 37C. Tamoxifen resistant (Tam-R) MCF-7 cells were kindly supplied by Julia Gee (Cardiff University, UK) and were derived and maintained as outlined previously (22) . For in vitro experiments, cells were seeded in growth media for 24 h followed by transfer to phenol red-and serum-free media (SFM; DMEM:Ham's nutrient mix F-12 supplemented with BSA (0.2 mg/ml), sodium bicarbonate (1.2 mg/ml), transferrin (0.01 mg/ml), L-glutamine (2 mM) and antibiotics as above) and dosed as specified below.
Cell proliferation assay
MCF-7, MDA-MB-231, T47D and Tam-R cells were exposed to caffeine (0-5 mM) or caffeic acid (0-50 μM) with or without tamoxifen (1 μM) for 48 h in SFM. Cell proliferation was period of 4 h prior to the end of the treatment protocol, as described in (23) . Total cell number and viability was assessed by trypan blue exclusion using a hemocytometer.
Cell cycle analysis
Cells were dosed with caffeine (0-5 mM) or caffeic acid (0-50 µM) in SFM for 48 h. 
Western Immunoblotting
Cells were exposed to caffeine (0-5 mM) or caffeic acid (0-50 μM) in SFM for 72 h after which cell lysates were prepared and protein concentration determined, as described previously (24) . 
Statistical analysis
Clinical data: Baseline characteristics of patients with low (≤1 cup/day), moderate (2-4 cups/day) or high (≥5 cups/day) coffee consumption were compared as specified by using Jonckheere-Terpstra test for continuous variables (not normally distributed) and Linear-bylinear association test for categorical variables. In survival analyses, patients were followed from inclusion until first breast cancer recurrence, last follow-up or death, whichever came first, prior to January 1, 2013. Of 1090 women, eight were excluded due to generalized disease within 3 months of diagnosis, leaving 1082 women included in the survival analyses.
Disease-free survival was estimated using Kaplan-Meier method. Log-Rank test was used for univariable survival analysis of the risk of early breast cancer recurrence in relation to coffee consumption. The influence of coffee consumption on prognosis was also analyzed using multivariable Cox regression to calculate hazard ratios (HR) with 95% confidence intervals (CI), adjusted for potential confounding factors; age (<60 years), histological grade III (yes/no), invasive tumor size (>20mm, or muscular or skin involvement) and any axillary lymph node involvement (yes/no). Since few patients had an invasive tumor size ≥51mm, or muscular or skin involvement, these patients were combined with the patients with invasive tumor sizes between 21 and 50mm in the multivariable analyses. All statistical analyses were performed using SPSS Statistics 19.0 software (IBM, Chicago, IL, USA). A P-value of <0.05 was considered statistically significant. Since this was an exploratory study, nominal P-values are presented without adjustment for multiple testing. 
Results
Associations between tumor size, ER status and coffee consumption among women with breast cancer
To evaluate the impact of coffee consumption on patient and tumor characteristics among women with breast cancer, coffee consumption was categorized into low (≤1 cup/day), moderate (2-4 cups/day), or high (≥5 cups/day), while no further definition of a cup was specified. Patient and tumor characteristics according to coffee consumption for the 1090 patients included in the study are shown in Table 1 . Women that were younger at their first full-term pregnancy showed a trend of drinking moderate to high amounts of coffee daily.
Additionally, the proportion of current smokers was higher with increasing coffee consumption, whereas the proportion of alcohol abstainers was higher with decreasing coffee consumption. Interestingly, moderate to high coffee consumption was associated with significantly smaller invasive tumor sizes (P trend =0.013), while concomitantly lower proportion of ER + tumors and conversely higher proportion of ER -tumors (P trend =0.018).
After stratification according to ER status (Table 2) , increasing coffee consumption remained significantly associated with smaller invasive tumor sizes among women with ER + tumors (P trend =0.009), while no significant association was found among ER -tumors (P trend =0.512).
However, a non-significant trend towards lower tumor proliferation measured by the Ki67 
Given the clinical observations of smaller breast tumor sizes and lower frequency of ER + tumors with increasing coffee consumption, we next examined how two major coffee constituents may affect breast cancer growth in relation to ER status at the cellular level.
Increasing doses of caffeine significantly suppressed the proliferation and total cell number of both ER-positive MCF-7 and ER-negative MDA-MB-231 (Fig. 1A) breast cancer cells, with a maximum inhibition at 5 mM, compared to control (P<0.01). At 1 mM caffeine, the proliferation was reduced by 80% in MCF-7 cells (P<0.01) and by 40% in MDA-MB-231 cells (P=0.054). Similarly, caffeic acid reduced both MCF-7 and MDA-MB-231 cell growth, although to a lesser extent than caffeine (Fig. 1A) . A concomitant increase in cell death was observed for MCF-7, but not for MDA-MB-231 (Fig. 1A) . The response to caffeine and caffeic acid were identical in the Tam-R cells as with the parental MCF-7 cells (Fig. 1B) . The caffeine-induced cell death in MCF-7 was associated with reduced pro-survival Bcl-xL levels while increased active caspase-7 and cleaved PARP, a signature event of apoptosis ( Fig. 1C and Supplementary Fig. S1 ). These results demonstrate that caffeine, but also caffeic acid, suppress the proliferation of human breast cancer cells and suggest that ER + tumors may be more sensitive to the growth inhibiting properties of the coffee constituents.
Coffee constituents impair the cell cycle progression in breast cancer cells
Having demonstrated that caffeine and caffeic acid suppressed the proliferation and viability of breast cancer cells, we further assessed their effect on cell cycle distribution. Increasing doses of caffeine resulted in impaired G 1 to S transition in both ER + MCF-7 (P≤0.003; Fig Although caffeic acid reduced MCF-7 and MDA-MB-231 cell densities (Fig 2A and B) , only
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minor modulations of the cell cycle distribution by caffeic acid were observed in the ER + ( Fig. 2A and C) as well as ER -cells (Fig. 2B and D) .
Caffeine and caffeic acid alters hormone receptor levels and downstream effectors in breast cancer cells
The role of coffee constituents in modulating molecular mechanisms with impact on breast cancer cell growth in relation to ER status was further investigated. Exposure to caffeine significantly reduced the ER abundance in ER + MCF-7 cells. In fact, 5 mM caffeine almost completely abolished the ER levels (Fig. 3A) . Although a ~50% reduction of MCF-7 proliferation was obtained by caffeic acid treatment, the effect on ER abundance was less pronounced (Fig. 3A) . The ER suppression was associated with a concomitant cyclin D1 decrease, and no detectable levels remained after 5 mM caffeine exposure (Fig. 3A) . In contrast, caffeine exposure resulted in re-expression of ER and cyclin D1 in ER -MDA-MB-231 cells (Fig. 3B) . However, caffeine did not under these conditions re-activate ER protein expression to the endogenous ER levels seen in untreated MCF-7 cells.
Caffeine exposure was further associated with a 70% and a 25% reduction in IGF-IR abundance in MCF-7 ( Fig. 3A) and MDA-MB-231 cells (Fig. 3B) , respectively, when compared to control. Increasing doses of caffeine resulted in a concomitant dose dependent and complete inhibition of Akt Ser473 phosphorylation in both MCF-7 and MDA-MB-231 cells (Fig. 3) . In line with the lower magnitude in growth inhibition by caffeic acid, a 30% reduction in IGF-IR levels was observed for MCF-7, but not for MDA-MB-231 cells, although a ≥50 % reduction in Akt phosphorylation was found for both cell types following caffeic acid exposure. These results demonstrate that caffeine and caffeic acid significantly alter ER and cyclin D1 levels, and suppress the IGF-IR/pAkt signaling pathway in both ER Finally, the present study demonstrate that tamoxifen-treated women with ER + tumors drinking two or more cups of coffee per day show a significantly reduced risk of early breast cancer recurrence, compared with women with low daily coffee consumption.
Several epidemiological reports suggest that coffee consumption decreases breast cancer risk (14, (25) (26) , while other studies report no association between coffee intake and breast cancer risk (27). However, relatively few studies have examined the association with risk or progression by estrogen receptor status. Sweden is among the top coffee consuming countries worldwide, and less than 1% of the coffee consumed is decaffeinated (28 (25) . While at the same time, no association with caffeine intake and overall breast cancer risk in the Women's Health Study was reported, the proportion of ER + tumors was decreased and the proportion ER -tumors increased ( inhibitory effects by the coffee constituents compared to ER -cells. Interestingly, the growth inhibitory property by caffeine on ER-positive MCF-7 cells was associated with a significant reduction in ER abundance. A moderate effect was also found for caffeic acid.
Downregulation of ER function and expression with subsequent growth inhibition has
previously been demonstrated for green tea polyphenolic catechenins (EGCC) and the structurally related plant flavonoid wogonin (12) (13) . In a similar manner to these dietary constituents, caffeine mimicked the actions of the antiestrogen fulvestrant (ICI 182,780) which inhibits ER-dependent functions and decreases ER expression resulting in suppression of tumor cell growth (36) . Similarly, endoxifen, the bioactive metabolite of tamoxifen, inhibits estrogen-induced breast cancer growth by competitively binding ER, leading to inhibition of ER-transcriptional activity and targeting ER to proteasomal degradation (37) .
Additionally, a recent study described that a derivative of caffeic acid (CAPE) specifically bound and down-regulated ER expression (38) .
Caffeine affected ER levels differently in ER-positive versus ER-negative breast cancer cell lines. Surprisingly, the caffeine and caffeic acid-induced growth inhibition of ER-negative MDA-MB-231 cells was associated with a re-expression of ER protein abundance. MDA-
MB-231 cells have densely methylated ER CpG islands and epigenetic repression via
promoter methylation has been suggested to be the predominant mechanism for ER downregulation in ER-negative tumors (39) . Caffeic acid has been reported to influence epigenetic repression and to reactivate methylation-silenced genes (40) . However, the modulation of ER levels in the present study appeared to involve other mechanisms as initial investigation of the methylation of the ER promoter using Combined Bisulphite Restriction
Assay revealed no effect of the coffee constituents (data not shown). GAPDH is shown as loading control. One representative image from at least three independent experiments is shown. 
